And that’s when we heard that MassHealth would stop covering GLP-1s for obesity entirely, effective July 1, 2026. Only thirteen state Medicaid programs covered GLP-1s for obesity at the start of 2026, down from sixteen the year before. But here’s the thing: When effective medication disappears, patients don’t stop needing treatment. America has always been better at treating disease than preventing it, and GLP-1s have exposed that logic at its starkest. Congress should remove that exclusion and treat obesity the way we treat every other chronic condition—before the complications arrive, not after.